Real‐world treatment patterns of metastatic non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors

BACKGROUND: Several epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) have been approved for first‐line (1L) treatment of EGFR‐mutated metastatic non‐small cell lung cancer (mNSCLC) in the United States (US). Real‐world analyses of 1L treatment patterns with EGFR TKIs, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Shenolikar, Rahul, Liu, Sizhu, Shah, Anne, Tse, Jenny, Cao, Yao, Near, Aimee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844647/
https://www.ncbi.nlm.nih.gov/pubmed/35702932
http://dx.doi.org/10.1002/cam4.4918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844647/
https://www.ncbi.nlm.nih.gov/pubmed/35702932
http://dx.doi.org/10.1002/cam4.4918

Ejemplares similares